Guardant Health, Inc. (GH)
| Market Cap | 13.25B +123.7% |
| Revenue (ttm) | 1.08B +39.6% |
| Net Income | -433.19M |
| EPS | -3.40 |
| Shares Out | 132.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,547,024 |
| Open | 96.94 |
| Previous Close | 96.71 |
| Day's Range | 95.00 - 100.73 |
| 52-Week Range | 36.36 - 120.74 |
| Beta | 1.49 |
| Analysts | Strong Buy |
| Price Target | 120.58 (+20.65%) |
| Earnings Date | May 7, 2026 |
About GH
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transc... [Read more]
Financial Performance
In 2025, Guardant Health's revenue was $982.02 million, an increase of 32.88% compared to the previous year's $739.02 million. Losses were -$416.28 million, -4.61% less than in 2024.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price target is $120.58, which is an increase of 20.65% from the latest price.
News
Guardant Health Transcript: Bank of America Global Healthcare Conference 2026
Strong Q1 results led to raised full-year guidance, driven by oncology and Shield test volumes. Growth is supported by the Smart Platform, AI integration, and expanding commercial initiatives, with further upside expected from ACS guideline changes and FDA approvals. Margin improvements and heavy investment in screening position the company for breakeven by 2027.
Guardant Health price target raised to $135 from $130 at Piper Sandler
Piper Sandler analyst David Westenberg raised the firm’s price target on Guardant Health (GH) to $135 from $130 and keeps an Overweight rating on the shares. The firm believes Guardant…
Guardant Health price target raised to $95 from $90 at Evercore ISI
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Guardant Health (GH) to $95 from $90 and keeps an In Line rating on the shares. Published first on…
Guardant Health price target raised to $129 from $120 at Baird
Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Guardant Health (GH) to $129 from $120 and keeps an Outperform rating on the shares. The firm updated its…
Guardant Health price target raised to $135 from $130 at JPMorgan
JPMorgan raised the firm’s price target on Guardant Health (GH) to $135 from $130 and keeps an Overweight rating on the shares.
Guardant Health price target raised to $120 from $115 at Barclays
Barclays raised the firm’s price target on Guardant Health (GH) to $120 from $115 and keeps an Overweight rating on the shares.
Guardant Health reports Q1 adjusted EPS (45c), consensus (47c)
Reports Q1 revenue $301.7M, consensus $279.06M. “Our first-quarter revenue increased 48% year over year, reflecting strong momentum across the Guardant portfolio,” said Helmy Eltoukhy, co-founder and ...
Guardant Health raises FY26 revenue view to $1.3B-$1.32B from $1.25B-$1.28B
Consensus $1.27B. Guardant Health (GH) continues to expect full year 2026 non-GAAP gross margin to be in the range of 64% to 65%. Guardant Health now expects total non-GAAP operating…
Guardant Health Earnings Call Transcript: Q1 2026
Q1 2026 saw 48% revenue growth to $302M, driven by strong oncology, biopharma, and screening performance. Raised full-year guidance to $1.30–$1.32B, with Shield and Guardant360 products leading growth and continued investment in commercial expansion.
Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 ...
Guardant Health receives FDA approval for Guardant360 CDx
Guardant Health (GH) announced that the U.S. Food and Drug Administration, FDA, has approved the Guardant360 CDx liquid biopsy test as a companion diagnostic for Veppanu. Veppanu, jointly developed by...
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant...
Guardant falls after FDA panel votes down AstraZeneca breast cancer drug
Guardant Health (GH) shares are down 4% to $79.73 in midday trading.
Guardant Health announces multi-year strategic collaboration with Nuvalent
Guardant Health (GH) announced a multi-year strategic collaboration with Nuvalent (NUVL) to support the development and potential commercialization of Nuvalent’s oncology pipeline using the tissue and...
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a...
Guardant Health to Participate in Upcoming Investor Conferences
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. B...
Overhang should lift for Guardant after AstraZeneca AdCom, says Leerink
Leerink notes that Guardant Health (GH) shares have reacted negatively to the release of FDA briefing documents for AstraZeneca’s (AZN) camizestrant Advisory Committee meeting as the briefing document...
Guardant falls after FDA briefing documents for camizestrant
Shares of Guardant Health (GH) are moving lower after the FDA posted briefing documents for AstraZeneca’s (AZN) camizestrant ahead of the committee meeting on April 30. Guardant’s G360 test is…
Guardant Health Chief Medical Officer resigns effective May 8
On April 27, 2026, Guardant Health (GH) announced the resignation of Craig Eagle, M.D., the Company’s Chief Medical Officer, to be effective as of May 8, 2026. Published first on…
Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2026 after market c...
Guardant Health price target lowered to $115 from $130 at Barclays
Barclays analyst Luke Sergott lowered the firm’s price target on Guardant Health (GH) to $115 from $130 and keeps an Overweight rating on the shares. The firm adjusted targets in…
Citi adds ‘upside 90-day catalyst watch’ on Guardant Health
Citi added an “upside 90-day catalyst watch” on shares of Guardant Health (GH) while keeping a Buy rating on the name with a $150 price target Citi sees upside to…
Guardant Health price target lowered to $90 from $110 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Guardant Health (GH) to $90 from $110 and keeps an In Line rating on the shares as part of…
Guardant Health added to Q2 Tactical Ideas List at Wells Fargo
Wells Fargo added Guardant Health (GH) to the firm’s Q2 Tactical Ideas List. Following the recent pullback, the firm sees multiple catalysts not baked into the 2026 guide that could…
Guardant Health announces evidence generated from InfinityAI
Guardant Health (GH) announced that real-world evidence generated from Guardant’s InfinityAI contributed to the recent approval of ENHERTU, developed and commercialized by Daiichi Sankyo in Japan, for...